We have briefly evaluated the Biometic Imaging instrument IMAGN for the quantitation of CD34 cells in peripheral leukapheresis samples. The comparison is against a flow method using the ISHAGE staining and gating protocol. Before we decide whether or not to continue our evaluation I have some questions for other centers that have switched from flow to this method: 1. Does anyone have data comparing the cell dose calculated by flow to the IMAGN cell dose with corresponding patient engraftment data? 2. Were your cell dose goals for leukapheresis harvests adjusted due to the implementation of the IMAGN method? 3. Does anyone have data on how the fluorescence intensity cutoff in the IMAGN was determined? 4. Does anyone know whether or not the dim CD34 cells which are below the IMAGN cutoff are OK to ignore (not count)? 5. What are other centers doing about the possible use of CD34 in peripheral blood to predict when, and for how long, to harvest? 6. Any experience with reproducibility of the CD34 result if the sample is tested the day it is collected versus the next day (and what medium, cell conc., temp the sample is held at)? Any other comments about this would be appreciated Tom McHugh UCSF Medical Center/Stanford University Hospital mchugh@pangloss.ucsf.edu
This archive was generated by hypermail 2b29 : Wed Apr 03 2002 - 11:54:01 EST